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Abstract
Background: Diabetic neuropathy (DN) is a common complication of diabetes that has significant
economic burden, especially for patients with comorbid depression or anxiety. This study examines
and quantifies factors associated with healthcare costs among patients diagnosed with diabetic
neuropathy (DN) with or without a comorbid diagnosis of depression or anxiety (DA) using
retrospective administrative claims data. No study has examined the differences in economic
outcomes depending on the presence of comorbid DA disorders.
Methods: Over-age-18 individuals with 1+ diagnosis of DN in 2005 were selected. The first
observed DN claim was considered the "index date." All individuals had a 12-month pre-index and
follow-up period. For both under-age-65 commercially insured and over-age-65 individuals with
employer-sponsored Medicare supplemental insurance, we constructed 2 subgroups for individuals
with DA (DN-DA) or without (DN-only). Patients' clinical characteristics over pre-index period
were compared. Multivariate regressions were performed to assess whether DN-DA patients had
higher utilization of healthcare resources and costs than DN-only patients, controlling for
demographic and clinical characteristics.
Results: We identified 16,831 DN-only and 1,699 DN-DA patients in the Medicare supplemental
cohort, as well as 17,205 and 3,105 in the commercially insured. DN-DA patients had higher
prevalence of diabetes-related comorbidities for cardiovascular disease, cerebrovascular/
peripheral vascular disease, nephropathy, obesity, and hypoglycemic events than DN-only patients
(all p < 0.05). Controlling for differences in demographic and clinical characteristics, DN-DA
patients had $9,235 (p < 0.05) higher total healthcare costs than patients with DN-only among
those with Medicare supplemental coverage ($26,718 vs. $17,483), and $10,389 (p < 0.05) more
total costs among commercially insured ($29,775 vs. $19,386). Factors associated with increased
costs included insurance type, geographical region, diabetes-related comorbidities, and insulin
therapy.
Conclusion: These findings indicate that the healthcare costs were significantly higher for DN
patients with depression or anxiety relative to those without such comorbid disorders.
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Background
Diabetes mellitus is a chronic condition that has been esti-
mated to affect over 20 million people or 7% of the total
population in the U.S. in 2005 [1]. Diabetic neuropathy
(DN) is a common complication of diabetes, in which
nerves are damaged as a result of hyperglycemia. Painful
DN manifests itself as an electric, burning, or shooting
sensation; however patients with DN can also be asymp-
tomatic. Risk factors for DN include hyperglycemia,
hyperlipidemia, high blood pressure, obesity, age of
at least 40 years, and having diabetes for at least 25 years
[2-4].
The economic burden of symptomatic and non-sympto-
matic DN is significant. The total annual direct costs of
DN and its complications in the U.S. were $4.6–13.7 bil-
lion in 2001 [5]. Patients with DN had significantly
higher total medical costs than individuals with diabetes
but no DN [6]. It has been shown that more than one
quarter of total direct costs for diabetes in the U.S. can be
attributed to DN [5]. The indirect costs of DN, including
missed days of work and decreased productivity, are a
considerable component of total costs [7]. Recent research
suggests that DN symptoms cause workers to lose approx-
imately $3.65 billion per year in health-related lost pro-
ductivity [7].
Compared to the general U.S. population, diabetic
patients are twice as likely to be diagnosed with depres-
sion [8]. Prior studies have estimated that 28% of DN
patients have depression and 35% have moderate to
severe anxiety [9,10], and a more recent multi-center
study reported that 59% of DN patients had either condi-
tion [11]. The healthcare resource utilization and associ-
ated treatment costs for patients with diabetes comorbid
with DN or depression are much higher than those with-
out [6]. However, little has been done to examine resource
utilization and costs among DN patients, and no study
has examined the differences in these outcomes depend-
ing on the presence of comorbid depression or anxiety
disorders.
The aim of this study is to fill this gap by employing a ret-
rospective cohort design using a large US administrative
claims database to examine and quantify the economic
impact of comorbid depression or anxiety disorders on
healthcare resource utilization and associated costs for
DN patients. Findings from this study can be incorporated
into economic models of diabetes care and are relevant to
inform healthcare providers of diabetic patients and pol-
icy makers interested in the economic impact of DN.
Patients who were covered by commercial insurance (18–
64 years of age) and patients over age 65 with employer-
sponsored Medicare supplemental insurance were
assessed separately, and trends were compared across the
two populations. Multivariate regression analysis was
undertaken to examine the effects of having comorbid
depression or anxiety disorders on the likelihood and
number of healthcare services, as well as on costs after
controlling for differences in demographic and clinical
characteristics.
Methods
Data Source
The Thomson Medstat MarketScan Commercial Claims
and Encounters and Medicare Supplemental databases
(2004–2006) were used for the analysis for patients aged
18–64 and 65+, respectively. This database contains
administrative claims and eligibility records for approxi-
mately 20 million patients in distinct sets of files for com-
mercially insured (i.e., working age adults and their
dependants) and Medicare supplemental insured individ-
uals from approximately 45 large health plans geographi-
cally located in the United States. The databases include
separate files for enrollment records, medical and phar-
macy claims. The files are linkable based on an encrypted
patient identification number. Enrollment records con-
tain demographic information, including age, sex, and
geographic region. Medical claims files include inpatient,
outpatient, facility and services claims records. They
report up to 15 International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) codes for
diagnoses and up to fifteen ICD-9-CM procedures codes,
date of service, place of service, provider type, and plan
and patient paid amounts. Pharmacy claims files provide
information for each prescription with the National Drug
Code (NDC), dispense dates, quantity and days supplied,
and plan and patient paid amounts. Because data used in
this study were purchased from a third party which had
removed identifying information prior to its release, insti-
tutional review board (IRB) and similar approvals were
neither needed nor sought.
Identification of Study Population
Medical problems that each individual encountered were
identified based on ICD-9-CM codes associated with med-
ical claims. A patient diagnosed with diabetes (ICD-9-CM:
250.xx) was included in the study if the patient had at
least one DN claim (250.6x and/or 357.2) [12-14] in the
calendar year of 2005, and the first observed DN claim
was set as the index date. Patients may or may not have a
DN claim in the 12 months prior to the index date. Fur-
thermore, included patients were required to be at least 18
years of age as of the index date and to have continuous
health plan enrollment from 12 months prior to the index
date (i.e. pre-index period) through 12 months following
the index date (i.e. follow-up period).
We separately assessed study patients who were covered
by commercial insurance (working age adults 18–64 years
of age) and those of age 65 and above with employer-
sponsored Medicare supplemental insurance. For eachBMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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analysis, two study cohorts were identified based on the
presence of 1+ medical claim for depression (ICD-9-CM:
296.2, 296.3, 300.4, 309.1, 311.0) or for anxiety disorders
(ICD-9-CM: 300.0x, 300.2x, 300.3, 309.81) either in the
pre-index period or in the post-index period. DN patients
with depression and/or anxiety made up the "DN-DA"
cohort and those without such disorders constituted the
"DN-only" cohort.
Study Measures
Patient demographic characteristics in the pre-index
period included age, sex, and geographic regions (i.e.
northeast, north central, west, south). Dichotomous vari-
ables (1 = Yes, 0 = No) were created to measure clinical
characteristics over the 12 month pre-index period that
included: 1) use of insulin only, use of oral anti-diabetic
drugs (OADs) only, or use of insulin and OADs identified
based on the NDC codes in pharmacy claims; 2) the pres-
ence of diabetes-related co-morbidities and complications
identified based on ICD-9-CM codes in medical claims
such as:
￿ Cardiovascular disease (CVD; ICD-9-CM: 390-
398.xx, 401.x-403.xx, 404.1, 404.9, 405.xx, 410.xx-
417.x, 420.xx-429.xx),
￿ Cerebrovascular/peripheral vascular disease (CPVD;
ICD-9-CM: 430-437.x, 440.xx-444.xx, 447.x-454.x,
457.x-459.xx, 785.4),
￿ Diabetes related infections (ICD-9-CM: 038.xx,
790.7),
￿ Other metabolic diseases (ICD-9-CM: 251.3, 270.3,
276.xx),
￿ Nephropathy (ICD-9-CM: 580.9, 581.81, 581.9,
582.9, 583.xx, 588.8x, 593.9),
￿ Obesity (ICD-9-CM: 278.xx),
￿ Retinopathy (ICD-9-CM: 362.0x-362.2x, 362.41,
363.31, 365.44, 366.41),
￿ Hypoglycemic events (ICD-9-CM: 250.8x, 251.0–
251.2),
￿ Skin problems (ICD-9-CM: 680.x-686.xx, 707.xx),
and
￿ Leg amputation (ICD-9-CM: 278.80–278.82,
278.84, 278.86);
and 3) being hospitalized. Overall and diabetes-related
healthcare expenditures (in 2006 dollars) in the pre-index
period were also calculated. Diabetes-related expenditures
were estimated based on the medical service claims with
diabetes diagnoses (ICD-9-CM: 250.xx) coded anywhere
in the diagnosis file and medication costs recorded in the
pharmacy claims. Diabetes-related medication costs were
estimated based on prescription of insulin and OADs.
All-cause healthcare resource utilization and associated
direct costs in the follow-up period were quantified for
major service components. Specifically, the percentage of
patients with any medical services and the number of serv-
ices for each patient were calculated for components of
healthcare resource utilization including hospitalization,
skilled nursing facilities (SNF), emergency room (ER),
hospital outpatient, home health, and outpatient physi-
cian office visits. Similarly, DN-related healthcare utiliza-
tion and costs were extracted based on the medical service
claims with such diagnoses coded anywhere in the diag-
nosis file. DN-related medication costs were estimated
based on prescriptions of pharmacologic therapies recom-
mended for DN treatment [15]: 1) tricyclic antidepres-
sants, 2) venlafaxine, 3) duloxetine, 4) pregabalin, 5)
gabapentin, and 6) opioids (e.g., tramadol, oxycodone,
morphine, hydrocodone, methadone, levorphanol). All
costs included deductibles, copayments, coinsurance, and
coordination-of-benefits payments recorded in the data-
bases, and all costs were adjusted to 2006 U.S. dollars
using the medical component of the consumer price
index.
Analysis
Descriptive statistics were summarized. Percentages were
reported for categorical variables and cohort differences
were analyzed using Cochran-Mantel-Haenszel tests. For
continuous variables, mean and standard deviations were
reported and student t-tests were used to analyze cohort
differences. Logistic regressions were employed to analyze
effects of comorbid depression or anxiety disorders on the
likelihood of resource use. Ordinary least squares (OLS)
regressions were used to assess the association between
comorbid disorders and the number of services, whereas
generalized least squares models (assuming a gamma dis-
tribution specification) were employed for healthcare
costs. We conducted our analyses for commercially-
insured and Medicare-insured populations separately
because the reimbursed amount by Medicare is generally
lower than the commercial insurance companies. Explan-
atory variables in all regressions included age groups,
male gender, insurance type, geographic regions, each of
the diabetes-related complications and comorbidities
listed above, and pre-index use of insulin or OADs. All
analyses were conducted using SAS version 9.1 (SAS Insti-
tute, Inc., Cary, North Carolina), and findings of p values
of < 0.05 were considered statistically significant.BMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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Results
Sample Size
Figure 1 illustrates how sample size was attained for both
commercially insured and Medicare supplemental cov-
ered patients. Patients diagnosed with diabetes mellitus
and diabetic neuropathy in 2005 were included in the
study. Commercial patients age 18–64 years and Medicare
patients 65 years and older were required to be continu-
ously eligible from the 12 months prior through the 12
months after the index date. Furthermore, patients were
classified based on whether or not they were diagnosed
with depression or anxiety in the 12 months pre- or post-
index period.
Prevalence Estimates
About 50% of all patients diagnosed with diabetes in
2005 also had at least 1 DN diagnosis (Figure 1), which is
similar to the rate summarized in a recent review [16]. The
DN prevalence rate was slightly higher among patients
with Medicare supplemental insurance than those with
commercial coverage. Of all DN patients identified in
2005, approximately 4% were diagnosed with depression
and/or anxiety disorders, and the prevalence rate was
higher for females (5.1%) than for males (3.4%) (data not
shown). About 3.1% of DN patients with Medicare sup-
plemental insurance had comorbid depression or anxiety
disorders compared with 5.4% among patients with com-
mercial coverage (data not shown).
Demographic Characteristics
The study identified a total of 18,530 DN patients of age
65 and above with Medicare supplemental insurance, of
whom 1,699 (9%) were in the DN-DA cohort (Table 1).
Among those in the DN-DA cohort, 67.9% with depres-
sion only, 21.7% were diagnosed with anxiety only, and
10.4% had both depression and anxiety. Of the 20,310
commercially insured working age patients between 18–
64 years of age, 3,105 (15%) were in the DN-DA cohort.
The majority of patients in the DN-DA cohort (68.3%)
were diagnosed with depression only, 18.3% were diag-
nosed with anxiety only, and 13.4% had both depression
and anxiety. The mean age was similar between DN-only
Sample size of study population Figure 1
Sample size of study population.
                Medicare Supplemental Insurance    Commercial Insurance
Diagnosed 
with diabetes 
mellitus in 
2005 
n= 81,519 
Diagnosed 
with diabetic 
neuropathy in 
2005 
n= 41,167 
Age 65 and 
above and 
continuously 
eligible 
n= 18,530 
Not diagnosed 
with anxiety 
or depression 
in the pre- and 
post-index 
period 
n= 16,831 
Diagnosed 
with anxiety or 
depression in 
the pre- and 
post-index 
period 
n= 1,699 
Diagnosed 
with diabetes 
mellitus in 
2005 
n= 86,773 
Diagnosed 
with diabetic 
neuropathy in 
2005 
n= 42,519 
18-64 years of 
age and 
continuously 
eligible 
n= 20,310 
Not diagnosed 
with anxiety or 
depression in 
the pre- and 
post-index 
period 
     n= 17,205 
Diagnosed 
with anxiety or 
depression in 
the pre- and 
post-index 
period 
      n= 3,105 BMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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and DN-DA patients (76 vs. 75 years, p = 0.44) among
those with Medicare supplemental insurance, however,
DN-DA patients among the commercially insured were
significantly younger than DN-only patients (54 vs. 55
years, p < 0.05). The DN-DA cohort of both patient popu-
lations had a significantly lower proportion of male
patients (44% vs. 53% for those with Medicare supple-
mental insurance, 41% vs. 54% for the commercial
insured, both p < 0.05) than the DN-only cohort. The
majority of Medicare supplemental insured patients were
enrolled in health plans with comprehensive coverage,
while the majority of commercially insured patients had
coverage through preferred provider organizations (PPO).
Clinical Characteristics
The top 3 most prevalent comorbidities were CVD, CPVD,
and skin problems for both cohorts across populations
(Table 2). The DN-DA patients had significantly higher
prevalence rate for all diabetes-related complications and
comorbidities (all p < 0.05) except retinopathy than the
DN-only patients in both populations. Compared with
commercially insured DN patients, those with Medicare
supplemental insurance had higher prevalence rate for
CVD, CPVD, other metabolic disease, nephropathy, skin
problems, and infections related to diabetes.
Compared with the DN-only cohort, a significantly higher
proportion of DN-DA patients were prescribed insulin for
both the Medicare supplemental insured (40% vs. 36%, p
< 0.05) and the commercially insured (50% vs. 45%, p <
0.05). The percentage of patients with any inpatient
admission was significantly higher for the DN-DA cohort
compared to the DN-only cohort for both populations
(46% vs. 28% among Medicare supplemental insured,
36% vs. 20% among commercially insured, both p <
0.05). The overall and diabetes-related healthcare expen-
Table 1: Pre-index demographic characteristics by insurance type and cohort
Medicare supplemental insurance Commercial insurance
DN-only DN-DA DN-only DN-DA
# Observations 16,831 1,699 p-value* 17,205 3,105 p-value*
Age (mean, SD) 75.6 (6.1) 75.4 (6.3) 0.44 55.0 (7.4) 53.7 (7.7) < 0.05
Male (%) 52.9 44.2 < 0.05 53.7 41.1 < 0.05
Plan types (%)** < 0.05 0.54
Comprehensive 65.2 60.4 16.1 17.3
PPO 21.6 21.9 47.3 45.8
HMO 11.8 16.5 20.3 22.8
Other 0.3 0.1 15.6 13.3
Missing 1.1 1.0 0.8 0.9
Region (%) < 0.05 0.19
Northeast 10.8 8.5 8.1 8.0
North central 41.3 42.1 29.9 31.4
South 30.2 28.4 43.2 38.6
West 16.7 20.1 18.0 21.1
Missing 1.0 0.9 0.7 0.9
Source: Thomson Medstat MarketScan database for patients with Medicare supplemental and commercial insurance (2004–2005)
* Student t-tests for continuous variables and Cochran-Mantel-Haenszel tests for categorical variables were performed.
** HMO = Health Maintenance Organization; PPO = Preferred Provider OrganizationBMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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ditures for the Medicare supplemental insured patients
were approximately $10,000 and $3,500 higher (both p <
0.05), respectively, for the DN-DA cohort. For commer-
cially insured patients, the difference in the overall health-
care expenditures of DN-DA cohort over DN-only cohort
was approximately $12,000 (p < 0.05), while the differ-
ence in diabetes-related healthcare expenditures was
about $4,500 (p < 0.05).
Resource Utilization
A significantly higher percentage of DN-DA patients over
the follow-up period had inpatient hospital, SNF, ER, and
Table 2: pre-index clinical characteristics by insurance type and cohort
Medicare supplemental insurance Commercial insurance
DN-only DN-DA p-value* DN-only DN-DA p-value*
# Observations 16,831 1,699 17,205 3,105
Diabetes related complications and 
comorbidities (%)
Cardiovascular disease (CVD) 73.2 81.0 < 0.05 58.3 64.3 < 0.05
Cerebro/peripheral vascular disease 
(CPVD)
34.8 44.4 < 0.05 18.6 25.0 < 0.05
Other metabolic diseases 9.0 19.2 < 0.05 8.5 16.9 < 0.05
Nephropathy 7.5 10.4 < 0.05 7.0 8.6 < 0.05
Retinopathy 13.8 13.7 0.94 16.0 15.1 0.20
Hypoglycemic events 8.9 12.6 < 0.05 9.9 14.1 < 0.05
Skin problems 21.4 25.3 < 0.05 20.7 23.4 < 0.05
Infections related to diabetes 1.9 3.7 < 0.05 1.4 3.1 < 0.05
Obesity 1.3 3.1 < 0.05 3.8 9.2 < 0.05
Leg amputation 0.2 0.3 0.29 0.1 0.4 < 0.05
Anti-diabetic treatment (%)
No treatment 14.3 15.2 0.28 14.2 16.1 < 0.05
Insulin only 15.1 18.0 < 0.05 18.5 21.8 < 0.05
Oral antidiabetic agent only 49.5 44.6 < 0.05 41.2 33.4 < 0.05
Insulin with oral anti-diabetic therapy 21.1 22.1 0.34 26.2 28.7 < 0.05
Resource use and costs
% Patients with any hospitalization 28.0 46.0 < 0.05 20.1 35.7 < 0.05
Total diabetes-related healthcare 
expenditures$ (mean, SD)
$3,823 ($11,783) $7,384 ($21,727) < 0.05 $6,102 ($18,252) $10,580 ($29,887) < 0.05
Total healthcare expenditures$ 
(mean, SD)
$15,332 ($21,915) $25,514 ($38,869) < 0.05 $17,848 ($36,220) $30,352 ($52,812) < 0.05
Source: Thomson Medstat MarketScan database for patients with Medicare supplemental and commercial insurance (2004–2005)
* Student t-tests for continuous variables and Cochran-Mantel-Haenszel tests for categorical variables were performed.
$ Expenditures were adjusted to 2006 dollars using the medical component of the consumer price index. SD = standard deviation.BMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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hospital outpatient encounters than DN-only patients in
both populations, and DN-DA patients also had longer
hospital days, more SNF admissions, and more outpatient
physician office visits (Table 3). After controlling for
demographic and clinical characteristics in pre-index
period, patients with DN-DA were twice as likely to be
hospitalized and to have an ER visit as the DN-only
patients, and incurred 3 additional hospital days (both p
< 0.05).
Compared with the commercially insured, a higher pro-
portion of DN-DA (54% vs. 44%) and DN-only patients
(35% vs. 26%) with Medicare supplemental insurance
were hospitalized (Table 3). For both the DN-only and
Table 3: Resource use in post-index 12 months by insurance type and cohort
Medicare supplemental insurance Commercial insurance
DN-only DN-DA Odds ratio
(95% confidence interval) 
or adjusted mean 
difference
(p-value)
DN-only DN-DA Odds ratio
(95% confidence interval) 
or adjusted mean 
difference
(p-value)
# Observations 16,831 1,699 17,205 3,105
Inpatient hospital 
admissions
% patients with any 
admission
34.8% 54.3% 2.0 (1.8, 2.2)1 25.6% 43.7% 2.0 (1.8, 2.2)1
Number of hospitalized 
days (mean, SD)
2.6 (8.0) 6.0 (13.4) 2.8 (<0.05)2 2.5 (9.1) 5.8 (14.5) 2.5 (<0.05)2
SNF admissions
% patients with any 
admission
9.5% 25.3% 2.9 (2.6, 3.3)1 1.9% 4.7% 2.0 (1.6, 2.5)1
Number of admissions 
(mean, SD)
0.8 (3.9) 3.2 (8.8) 2.1 (<0.05)2 0.1 (1.5) 0.4 (3.0) 0.04 (<0.05)2
% patients with any ER 
visit
21.7% 38.8% 2.1 (1.9, 2.3)1 22.8% 37.6% 1.8 (1.6, 2.0)1
% patients with any 
hospital outpatient visit
78.1% 81.9% 1.3 (1.1, 1.5)1 75.0% 82.4% 1.5 (1.3, 1.6)1
Outpatient physician 
office visits
% patients with any visit 98.8% 98.1% 0.7 (0.4, 0.95)1 99.3% 99.6% 1.6 (0.9, 2.9)1
Number of visits 
(mean, SD)
18.5 (12.9) 21.6 (15.1) 2.5 (<0.05)2 16.7 (13.1) 24.9 (17.6) 7.1 (<0.05)2
Home health care visits
% patients with any visit 52.5% 52.4% 1.0 (0.9, 1.1)1 36.5% 45.7% 1.3 (1.2, 1.4)1
Number of visits 
(mean, SD)
2.2 (4.8) 2.6 (5.5) 0.2 (0.06)2 2.1 (7.1) 3.2 (8.6) 0.6 (<0.05)2
Source: Thomson Medstat MarketScan database for patients with Medicare supplemental and commercial insurance (2004–2005)
1Adjusted odds ratio and 95% confidence interval estimated from logistic regression.
2Adjusted mean difference and p-value estimated from ordinary least squares regression.BMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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DN-DA cohorts, the population with Medicare supple-
mental insurance also had higher utilization rates of SNF
admissions as well as home health care visits. Emergency
room, hospital outpatient, and physician office encoun-
ters were similar between both populations.
Healthcare Costs
Patients in the DN-DA cohort had higher raw total cost
and all its components than those in the DN-only cohort
for both populations (Table 4). After adjusting for demo-
graphic and clinical characteristics in pre-index period,
DN-DA patients with Medicare supplemental insurance
had $9,235 (p < 0.05) significantly higher total costs com-
pared with those with DN-only ($26,718 vs. $17,483,
data not shown), with the most cost differences from
inpatient admission ($4,781, p < 0.05) followed by SNF
($1,654, p < 0.05), outpatient prescription ($718, p <
0.05) and hospital outpatient services ($607, p < 0.05).
Among the commercially insured, DN-DA patients
incurred $10,389 (p < 0.05) significantly higher adjusted
total costs compared to the DN-only patients ($29,775 vs.
$19,386 data not shown), with the biggest cost differences
Table 4: Healthcare costs in post-index 12 months by insurance type and cohort
Medicare supplemental insurance Commercial insurance
DN-only* DN-DA* Adjusted cost 
difference1
(p-value)
DN-only* DN-DA* Adjusted cost 
difference1
(p-value)
Overall healthcare 
expenditures
(mean, SD):
Inpatient hospital $5,405 ($18,093) $11,544 ($34,481) $4,781 ** $7,864 (30,569) $15,994 ($38,452) $5,749**
Skilled nursing 
facility
$661 ($4,040) $2,581 ($8,326) $1,654 ** $181 ($2,471) $427 ($2,994) $171 **
Emergency room $89 ($452) $229 ($797) $91 ** $234 ($1,037) $564 ($1,967) $241 **
Hospital outpatient $2,606 ($9,397) $3,550 ($7,589) $607 ** $4,169 ($12,507) $6,323 ($18,333) $1,371 **
Outpatient 
physician office
$2,959 ($4,556) $3,435 ($3,921) $284 ** $2,815 ($4,930) $4,083 ($6,192) $977 **
Home health care $532 ($2,797) $614 ($2,063) $15 $671 ($3,884) $1,133 ($6,312) $235 **
Prescription 
medications
$4,286 ($3,913) $5,185 ($4,708) $718 ** $4,257 ($6,538) $6,001 ($6,538) $1,361 **
Total $18,072 ($26,660) $30,410 ($46,083) $9,235 ** $22,437 ($44,179) $38,200 ($56,718) $10,389 **
DN-related 
healthcare 
expenditures 
(mean, SD):
Inpatient $1,165 ($7,544) $2,947 ($12,387) $1,365 ** $2,461 ($12,422) $5,518 ($19,000) $2,084 **
Outpatient $420 ($1,508) $592 ($2,250) $91 ** $616 ($2,321) $706 ($2,282) $31
Pharmacy $189 ($549) $364 ($743) $172 ** $275 ($994) $666 ($1,457) $294 **
Total $1,773 ($7,749) $3,904 ($12,864) $1,594 ** $3,353 ($12,821) $6,890 ($19,442) $2,432 **
Source: Thomson Medstat MarketScan database for patients with Medicare supplemental and commercial insurance (2004–2005)
* Mean and standard deviation (in parentheses) are reported for each healthcare service. Expenditures were adjusted to 2006 dollars using the 
medical services component of the consumer price index.
1Adjusted difference estimated from generalized least squares regression with a gamma distribution specification.
** Denotes p < 0.05.BMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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from inpatient hospitalizations ($5,749, p < 0.05), hospi-
tal outpatient ($1,371, p < 0.05), pharmacy services
($1,361, p < 0.05), and outpatient physician office visits
($977, p < 0.05). For both populations, DN-DA patients
had significantly higher DN-related healthcare costs for all
components than DN-only patients controlling for differ-
ences in demographics and clinical characteristics. More
than 85% of the difference in adjusted total DN-related
healthcare costs between patients in DN-DA and DN-only
cohorts was from inpatient service for both Medicare sup-
plemental and commercial insured, followed by phar-
macy expenditures contributing additional 11% or 12%,
respectively.
Discussion
Using the administrative claims from the Thomson Med-
Stat MarketScan databases, this study was the first to
examine the impact of comorbid depression and anxiety
disorders on healthcare resource use and costs among DN
patients separately for the Medicare supplemental insured
patients and the commercially insured. Not only were DN
patients with depression or anxiety disorders more likely
to have encounters for inpatient hospitalization, ER, SNF,
and outpatient hospital services than those without such
disorders, they also had longer hospital days, more SNF
admissions, and more ER and outpatient hospital visits.
While the likelihood of using outpatient physician office
services was not different between DN-DA and DN-only
cohorts, the former was associated with a significantly
higher number of the services over the one year follow-up
period. Controlling for differences in demographic and
clinical characteristics, patients in the DN-DA cohort had
significantly higher total costs and higher costs for each of
the components than those in the DN-only cohort. For
both cohorts in each population, inpatient hospital costs
constituted the largest proportion of overall costs. Outpa-
tient prescriptions and hospital outpatient costs were
ranked as the second and third highest cost items for the
Medicare supplemental insured DN patients; however,
they contributed to similar proportion of the total costs
for the commercially insured sample.
For both the commercially insured and the Medicare sup-
plemental insured DN patients, the prevalence rates of all
other diabetes-related complications and comorbidities
except retinopathy were higher among those in the DN-
DA cohort than those in the DA-only cohort. Specifically,
the biggest differences in prevalence rates between those
cohorts were in CVD, CPVD, and other metabolic dis-
eases. Although it is unclear about the causality between
depression/anxiety and other diabetes-related complica-
tions and comorbidities among DN patients, special
attention is needed to monitor other diabetes-related
complications and/or comorbidities when managing DN
patients comorbid with depression and/or anxiety.
This study found lower utilization rates of many compo-
nents of healthcare services among the commercially
insured patients compared with those with Medicare sup-
plemental insurance. This is especially true for hospital
and SNF admissions, as well as home health care visits.
However, healthcare costs were higher among the com-
mercially insured patients. One possible explanation for
this finding is that the various resource-based payment
systems currently employed by Medicare have made the
unit cost per healthcare service less expensive than similar
services covered by commercial insurance. Despite of the
difference between various payment systems, DN patients
with depression or anxiety disorders had over $9,000
more total costs than those without such disorders in both
populations after controlling for differences in patient
demographic and clinical characteristics.
The actual direct costs associated with DN treatment
could be much higher than what was captured in the
study since DN is under-reported to physicians and subse-
quently under-treated [17,18]. Older DN patients could
be less likely to seek treatment for depression or anxiety
disorders than younger patients. Previous research has
also found a high rate of comorbid anxiety disorders
among patients with depression [19]. Several intervention
trials have found that proper treatment for comorbid
depression among diabetes patients was associated with
lower medical costs [20-22]. Therefore, it is important to
recognize that the need for treatment of comorbid depres-
sion or anxiety disorders is considerable, particularly
among patients with Medicare supplemental insurance,
who were also associated with significantly higher levels
of resource use compared to the commercially insured
patients.
Several limitations need to be noted when interpreting
results for this study. Firstly, a selection bias could exist
where DN patients with comorbid depression or anxiety
disorders had unobserved heterogeneity that correlated
with levels of disease severities and study outcomes.
Despite the best efforts to capture patient heterogeneity by
demographic and clinical characteristics over pre-index
period, the study was unable to control for unobserved
confounding characteristics using a retrospective study
design. Secondly, as patients' actual medical records could
not be accessed for the study, the identification of DN,
depression or anxiety disorders and other diabetes related
complications and comorbidities were based on the ICD-
9-CM diagnosis codes in medical claims. This information
could be subject to clerical errors or other reporting errors,
leading to potentially inaccurate identification of patients'
conditions. Additionally, we only required 1 DN diagno-
sis to identify the DN cohort. We might misclassify some
of non-DN patients to the DN cohort due to coding errors.
Similarly, the study was unable to directly measure theBMC Health Services Research 2009, 9:111 http://www.biomedcentral.com/1472-6963/9/111
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severity of DN or depression or anxiety disorders, which
was found to be a significant predictor of healthcare utili-
zation and costs [23] and to be associated with decreased
quality of life outcomes [24]. Thirdly, our study did not
assess other pain related conditions between the study
cohorts. However, we are not aware of any published
studies that report differences in pain-related conditions
within subgroups of DN patients. Fourthly, the study cal-
culated direct treatment costs based on plan payment and
patient co-payment for each service, and therefore did not
capture other indirect costs incurred by patients such as
lost productivity and opportunity costs associated with
time lost seeking treatment. Also, as over-the-counter
medications were not captured in the administrative
claims databases, the study could be underestimating the
pharmacy utilization and thus associated costs. Further-
more, we may overestimate the diabetes- and DN-related
costs as we used diabetes or DN diagnoses recorded any-
where in the claims to assign such costs. We also lack of
information regarding the health plan-specific benefit
structure, which may influence healthcare utilization.
Finally, the results presented here could only be taken as
associations instead of causations. While the study found
that DN patients with comorbid depression or anxiety dis-
orders used more resources and incurred higher costs for
treatment, it cannot be established whether such
increased resource use and costs were a result of comorbid
disorders.
Conclusion
This study assessed healthcare resource use and costs
between patients diagnosed with DN with and without
diagnosed depression or anxiety disorders among those
aged 18–64 commercially insured and those of age 65 and
above with employer-sponsored Medicare supplemental
insurance. We found significantly higher healthcare
resource utilization and costs among DN patients who
had comorbid depression or anxiety disorders versus
those without such diagnoses, even after controlling for
demographic and clinical differences. Properly treating
these comorbid depression or anxiety disorders among
DN patients may have an impact on the economic burden
of DN.
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